Samsung Bioepis answers biologics question with resounding 'yes'

There is little doubt that, since it started life in the drug development industry just five years ago, Samsung Bioepis has passed its first test with flying colors.

That test was to become a major player in the development of biosimilar medicines, the area through which the company chose to enter the industry in February 2012.

At that time, Samsung Bioepis, which is a joint collaboration between Korean conglomerate Samsung and US biotech Biogen (Nasdaq: BIIB), quickly realized the value that biosimilars could bring to patients over the coming decades by bringing increased access to high-quality medicines, says company spokesman Mingi Hyun.